Using HCQ before treatment for advanced nasopharyngeal carcinoma
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
This study is testing if giving hydroxychloroquine to patients with advanced nasopharyngeal cancer before their treatment can help prevent cancer from coming back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Nantong, Jiangsu) |
| Trial ID | NCT06389201 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of pretreating advanced nasopharyngeal carcinoma (NPC) patients with hydroxychloroquine (HCQ) before they undergo radiotherapy and chemotherapy. The focus is on understanding how HCQ can inhibit the formation of dormant polyploid giant cancer cells (PGCCs), which are linked to cancer recurrence and metastasis. By analyzing the biological properties of PGCCs and their response to treatment, the study aims to improve patient outcomes and reduce the risk of cancer returning after initial therapy. The research utilizes a clinical model to assess the impact of HCQ on PGCC formation and overall survival rates in NPC patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients clinically diagnosed with nasopharyngeal carcinoma who have not yet received any cancer therapies.
Not a fit: Patients with metastatic disease prior to the first treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of cancer recurrence and improve survival rates for patients with advanced NPC.
How similar studies have performed: While the concept of targeting dormant cancer cells is gaining traction, this specific approach using HCQ in NPC is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of NPC. * Have not received any cancer therapies * Must provide informed consent Exclusion Criteria: * With metastasis before the first treatment.
Where this trial is running
Nantong, Jiangsu
- Bo You — Nantong, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Bo You, Doctor — Department of Otorhinolaryngology-Head and Neck Surgery, Affiliated Hospital of Nantong University
- Study coordinator: Bo You, Doctor
- Email: youbo19891014@163.com
- Phone: +8615851358688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.